Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,453 shares of the company’s stock after purchasing an additional 578 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Novo Nordisk A/S were worth $641,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $98,765,000. Wellington Management Group LLP purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $42,017,000. Sanctuary Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $41,646,000. Finally, World Investment Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on NVO shares. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

NVO stock opened at $85.00 on Wednesday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock’s 50 day moving average price is $95.10 and its 200 day moving average price is $114.43. The firm has a market cap of $381.45 billion, a P/E ratio of 27.51, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.